ѻý

<ѻý class="page-title">Meeting Coverage

EULAR

<ѻý class="page-description">European Alliance of Associations for Rheumatology
SpA Patients Do Just Fine Managing Their Own Follow-Up Care

Randomized trial suggests usual practice is wasteful

EULAR over a photo of Vienna Exhibition Center in Vienna, Austria.
<ѻý class="section_title">Latest EULAR Meeting Coverage
Izokibep Marches on for Psoriatic Arthritis

Early phase III data cement case for novel IL-17A inhibitor

June 16, 2024
Novel URAT1 Inhibitors Advance for Gout

New treatment options on the horizon come into better focus

June 14, 2024
OA Patients Get Long-Term Benefit From Lifestyle Improvements

Improvement in pain and function lasted well after formal program ended

June 14, 2024
Is 'Difficult-to-Treat' RA a Lost Cause?

The name says it all, but progress appears to be coming

June 13, 2024
CAR-T Treatment Continues to Astonish in Rheumatologic Diseases

Numbers of patients, length of follow-up keep growing with no visible downside (yet)

June 12, 2024
Phase II Study: Bispecific Oral Drug Tops Leading JAK Inhibitor for RA

Novel agent adds additional action in hopes of improving efficacy

June 6, 2023
Two-Drug Combo Wins for Refractory Gout

Phase III results back potential competitor for pegloticase-methotrexate treatment

June 3, 2023
First-in-Class Sjogren's Drug Passes Mid-Stage Test

Novel agent targets CD40 ligand

June 3, 2023
Cardiovascular Risk Models Still Fall Short for Arthritis Patients

Of three major prognostic tools, none hit the mark

June 2, 2023
More Evidence Backs Gout Benefit for Gliflozin Agents

New study finds marked risk reduction tied to drugs' urate-lowering effect

June 2, 2023
More Success for CAR T-Cell Therapy in Rheumatic Disease

Stunning improvement for two patients with rare form of autoimmune myositis

June 1, 2023
Trial Shows RA Can Be Stopped at Preclinical Stage

Familiar biologic halts progression in high-risk patients with just a few painful joints

June 1, 2023
Benefits Found for Hand OA Drug Treatments

In separate studies, one old standby and one newer biologic appeared helpful

May 31, 2023
TYK2 Inhibitor Shows Promise in Lupus

Latest indication for deucravacitinib seen as approvable for multiple rheumatologic conditions

June 4, 2022